| 1 |
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis [J]. N Engl J Med,2003,349(6):583-596.
|
| 2 |
Larsen CP, Walker PD, Weiss DT, et al. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies [J]. Kidney Int,2010,77(9):816-819.
|
| 3 |
von Hutten H, Mihatsch M, Lobeck H, et al. Prevalence and origin of amyloid in kidney biopsies [J]. Am J Surg Pathol, 2009, 33(8):1198-1205.
|
| 4 |
Sen S, Sarsik B. A proposed histopathologic classification, scoring,and grading system for renal amyloidosis: standardization of renal amyloid biopsy report [J]. Arch Pathol Lab Med, 2010, 134(4):532-544.
|
| 5 |
Yao Y, Wang SX, Zhang YK, et al. A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis [J]. Nephrol Dial Transplant,2013,28(3):689-697.
|
| 6 |
Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study [J]. Br J Haematol, 2013, 161(4):525-532.
|
| 7 |
姚英,王素霞,章友康,等. 205 例肾脏淀粉样变性病患者的分型诊断研究[J]. 中华肾脏病杂志,2013,29(2):88-92.
|
| 8 |
Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone,and melphalan, prednisone, and colchicine [J]. N Engl J Med,1997,336(17):1202-1207.
|
| 9 |
Skinner M,Sanchorawala V,Seldin DC,et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study [J]. Ann Intern Med,2004,140(2):85-93.
|
| 10 |
Palladini G,Perfetti V,Obici L,et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation [J]. Blood,2004,103 (8):2936-2938.
|
| 11 |
Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options [J]. J Clin Oncol, 2011, 29 (14):1924-1933.
|
| 12 |
Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response[J]. Haematologica,2007,92(10):1415-1418.
|
| 13 |
Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy[J]. Br J Haematol,2003,122 (1):78-84.
|
| 14 |
Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis [J]. Blood,2010,116(18):3426-3430.
|
| 15 |
Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [J]. N Engl J Med,2007,357(11):1083-1093.
|
| 16 |
Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients [J]. Blood, 1996,88(7):2801-2806.
|
| 17 |
Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients[J].Blood,2011,118(16):4346-4352.
|
| 18 |
邱志祥, 王茫桔, 王莉红, 等. 自体造血干细胞移植治疗原发性淀粉样变性的临床研究[J]. 中华血液病杂志, 2012,33(3):187-190.
|
| 19 |
Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006 [J]. Bone Marrow Transplant, 2011, 46 (7):970-975.
|
| 20 |
Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis:results of a phase 1 dose-escalation study [J]. Blood, 2009, 114(8):1489-1497.
|
| 21 |
Tamaki H,Naito Y,Lee-Kawabata M,et al. Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib [J]. Int J Hematol,2010,92(4):655-658.
|
| 22 |
Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis [J]. Ann Hematol,2011,90(2):201-206.
|
| 23 |
Landau H, Hassoun H, Bello C, et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis [J]. Amyloid,2011,18(Suppl 1):135-136.
|
| 24 |
Dispenzieri A,Lacy MQ,Rajkumar SV,et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis[J]. Amyloid,2003,10(4):257-261.
|
| 25 |
Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan,dexamethasone, and thalidomide [J]. Ann Hematol,2009,88(4):347-350.
|
| 26 |
Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis [J]. Blood, 2007, 109(2):457-464.
|
| 27 |
Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma[J]. Leukemia,2008,22(2):414-423.
|
| 28 |
Gertz MA. Immunoglobulin light chain amyloidosis:2011 update on diagnosis, risk-stratification, and management [J]. Am J Hematol,2011,86 (2):180-186.
|